Table 2.

Efficacy analysis.

Parameter
Median duration of treatment (weeks; range)	17 (6–116)
Cumulative dose of everolimus (mg; median, range)	1200 (440–8012)
Median duration of follow-up (weeks; range)	28 (17–147)
Best response by RECIST 1.0 (n, %)
Complete response	0 (0)
Partial response	0 (0)
Stable disease	5 (71)†
Progressive disease	2 (29)
Overall disease control	5 (71)
Median duration of SD (weeks; range)	24 (17–116)‡
Median PFS (weeks; 95% CI)	33 (8–56)
Median OS (weeks; 95% CI)	30 (15–45)

RECIST: Response Evaluation Criteria in Solid Tumors, SD: stable disease, PFS: progression-free survival, and OS: overall survival.

^†4 of 5 patients showed SD >24 weeks; ^‡at time of data analysis, 1 patient still had ongoing SD.